Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 163, 105319
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Effect of canagliflozin on liver function tests in patients with type 2 diabetesDiabetes & Metabolism, 2016
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MicePLOS ONE, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Nonalcoholic Fatty Liver DiseaseJAMA, 2015
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 studyCurrent Medical Research and Opinion, 2014
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- How does the DerSimonian and Laird procedure for random effects meta-analysis compare with its more efficient but harder to compute counterparts?Journal of Statistical Planning and Inference, 2010
- Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of EthnicityHepatology, 2004